Ivis Vinicius de Oliveira Martins de Oliveira Martins

Mr. Ivis Vinicius de Oliveira Martins de Oliveira Martins

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2024 in Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde
Verified
Journal Article
Open access
PDF file
BSBruno DA Silva
Bruno DA Silva
IMIvis Vinicius de Oliveira Martins de Oliveira Martins
Ivis Vinicius de Oliveira Martins de Oliveira Martins
BHBeatriz Hata
Beatriz Hata
MSMarcia DOS Santos
Marcia DOS Santos
PPPriscila Packeiser
Priscila Packeiser
FVFabiana Varallo
Fabiana Varallo
Objective: to estimate the prevalence of medication-induced delirium and drug-related problems (DRP) in older people hospitalized in intensive care unit (ICU). Methods: A systematic review were conducted in PubMed, EMBASE, LILACS, Ageline, Web of Science, and Cochrane databases (until March 2023). Clinical trials and observational studies that investigated the contribution of medication in the occurrence of delirium and compared with critically ill older patients (aged≥65 years old) without the syndrome were included. We excluded emergency departments, medical wards, primary and secondary healthcare levels, patients with delirium tremens; metabolic encephalopathy; dementia; palliative care; and brain metastasis. The references were entered into Rayyan QCRI. Two pairs of reviewers selected the articles, extracted data, and assessed the risk of bias (ROBINS-I). Results: Of 12,492 studies retrieved, after de-duplication exclusion (n=6,025), title/abstract (n=6,467) and full reading (n=286), two met the inclusion criteria. Both were observational (cohort), developed in high-income countries, with high level of risk of bias (overall). The frequency of delirium and subsyndromal delirium was 15.8% to 33.9%. Independent risk factors were the exposure of opioids and use of corticosteroids. Delirium increased the length of hospital stay in ICU, and the mechanical ventilation. Conclusion: Further studies are necessary to understand the DRP and characteristics of pharmacotherapy associated with delirium in critically ill older people. Adverse drug reactions and deliriogenic load seem to contribute to the occurrence of syndrome.

23 April 2020 in Research, Society and Development
Verified
Journal Article
Open access
PDF file
GSGlaydiane Alves de Sousa
Glaydiane Alves de Sousa
IMIvis Vinicius de Oliveira Martins de Oliveira Martins
Ivis Vinicius de Oliveira Martins de Oliveira Martins
VPVinícius Duarte Pimentel
Vinícius Duarte Pimentel
JSJoubert Aires Sousa
Joubert Aires Sousa
A presente pesquisa visou avaliar in silico a farmacodinâmica, farmacocinética e toxicidade dos ácidos siríngico e ursólico isolados da Actinidia deliciosa e analisar o mecanismo que fundamente a sua atuação na redução do colesterol comparando-os com o fármaco sinvastatina. Foi utilizado o servidor online PreADME para a avaliação do perfil farmacocinético e toxicológico por meio da estrutura-atividade molecular e o software AutodockVina para o estudo da farmacodinâmica e potencial farmacológico das interações moleculares. Os dados ADME obtidos para os ácidos siríngico e ursólico foram semelhantes aos da sinvastatina, na análise do docking molecular foi evidenciado que os resultados foram aproximados entre as moléculas testadas, contudo o ácido ursólico se sobrepôs com maior estabilidade de interação com o alvo biológico quando comparado a sinvastatina. Foi possível observar a partir dos resultados que os compostos avaliados são qualificados a posteriores ensaios in vitro e in vivo para um estudo mais aprofundado de sua ação anti-hiperlipêmica.

29 July 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
IMIvis Vinicius de Oliveira Martins de Oliveira Martins
Ivis Vinicius de Oliveira Martins de Oliveira Martins
VSValéria Semedo
Valéria Semedo
MPMaria Ivete Pedro
Maria Ivete Pedro
MMMariana Fragão Marques
Mariana Fragão Marques
JAJose Paulo Andrade
Jose Paulo Andrade
HRHugo Ribeiro
Hugo Ribeiro
Background: Home-based specialist palliative care (HBSPC) has been associated with symptom relief, improved quality of life (QoL), and optimization of care for patients with advanced illness. However, limited evidence is available regarding the integration of clinical outcomes, consultation duration, and exploratory value-based indicators in real-world HBSPC services. Objective: to evaluate clinical outcomes, consultation duration, and exploratory value-based efficiency indicators in an HBSPC service.Methods: a retrospective observational study was conducted using clinical records from presential HBSPC consultations. The final analytic sample included 168 valid patient records. Clinical outcomes assessed at baseline and 48-hour follow-up included symptom burden, complex palliative needs, and medication inadequacy. Consultation duration, number of visits, productivity indicators and exploratory outcomes, adjusted for consultation time, were also evaluated. Results were analyzed at the medical team level and presented as ranges of within-team variation.Results: significant clinical improvement was observed across all evaluated domains between baseline and 48-hour reassessment. Mean symptom burden improved by 2.89 points (p<0.001), while Palliative Outcome Scale (POS) improved by 7.6 points. Medication inadequacy decreased by a mean of 2.10 potentially inappropriate medications (PIMs). Patients meeting predefined admission criteria demonstrated greater improvement in symptoms and complex palliative needs than patients without formal admission criteria. Relevant within-team variability was observed regarding consultation duration and exploratory value-based indicators. Consultation duration ranged from 38.9 to 95.7 minutes, while symptom improvement adjusted to consultation time ranged from 0.96 to 7.38 points/hour. Longer consultations were not consistently associated with greater clinical improvement.Conclusions: presential HBSPC consultations were associated with early improvement in symptom burden, complex palliative needs, and medication adequacy. Additionally, the observed variability in outcomes, adjusted for consultation time, suggests that clinical value in palliative care may not be adequately reflected solely by consultation duration or activity volume. These findings reinforce the importance of multidimensional approaches for evaluating HBSPC services, including at the individual level for each professional.

15 May 2026 in Farmacia Hospitalaria
Verified
Journal Article
Open access
IMIvis Vinicius de Oliveira Martins de Oliveira Martins
Ivis Vinicius de Oliveira Martins de Oliveira Martins
IMIgor Massocatto Marques
Igor Massocatto Marques
FSFelipe Augusto Trinca Alves da Silva
Felipe Augusto Trinca Alves da Silva
MTMaria Eduarda Marques Trinca
Maria Eduarda Marques Trinca
LCLais Beanucci Coelho
Lais Beanucci Coelho
FVFabiana Rossi Varallo
Fabiana Rossi Varallo
Quality of life (QoL) is a central outcome in palliative care (PC), particularly in hospital settings, where patients often present with advanced illness, complex symptoms, and multidimensional needs. Accurate QoL assessment is essential to support patient-centered and family-centered decision-making; however, the diversity of available instruments and limited validation beyond oncology populations pose challenges for their clinical and research use. We aimed to identify tools measuring QoL in hospitalized PC patients, highlighting their domains and psychometric properties. A scoping review was conducted following Joanna Briggs Institute guidelines and the PRISMA Extension for Scoping Reviews (PRISMA-ScR). We searched MEDLINE (PubMed), CINAHL, EMBASE, The Cochrane Library, Scopus, Web of Science, Google Scholar, and LILACS from inception until April 11, 2025. Independent reviewers assessed eligibility, extracted data, and evaluated risk of bias. Of 6026 studies retrieved, after removing duplicates (n = 1680) and full-text screening (n = 17), 12 met inclusion criteria, including 5 validation, 5 observational studies and 2 clinical trials. Eight tools were identified, most originally developed for advanced-stage conditions and applied in high-income countries. Main domains included physical comfort (n = 7), psychological well-being (n = 7), and spiritual well-being (n = 7). Quality of death was assessed in one instrument. Two instruments were validated for Brazilian Portuguese, primarily for cancer patients. Frequently reported psychometric properties were face validity (n = 9), content validity (n = 6), and construct validity (n = 6). No gold-standard instrument exists for measuring QoL in PC. Selection should consider patient and family preferences, health status, prognosis, life expectancy, and intended use. Findings highlight the need for psychometrically robust instruments applicable across disease stages and conditions. Incorporation of death preparedness, quality of death, and patient- and family-centered outcomes remains limited but is important to guide individualized, safe, and equitable hospital-based PC.

30 July 2026 in Biochem
Verified
Journal Article
Open access
PDF file
ADAlexandra da Costa Duarte
Alexandra da Costa Duarte
RRRita Rodrigues-Lopes
Rita Rodrigues-Lopes
ASAna Isabel Severino
Ana Isabel Severino
MOMatilde Oliveira
Matilde Oliveira
IGInês Guerra
Inês Guerra
HRHugo Ribeiro
Hugo Ribeiro
Background/objectives: Benzodiazepines are widely prescribed as adjuvants in pain management, particularly for musculoskeletal conditions, with prescription rates for back and chronic pain more than doubling between 2003 and 2015. Yet, the evidence supporting this practice remains poorly defined. This study evaluates the efficacy of benzodiazepines in pain management, analyzing comparative data, pharmacological mechanisms, and global clinical guidelines. Methods: Narrative review informed by a predefined systematic search of PubMed, Scopus, Cochrane Library and Web of Science. We searched for direct comparative studies between diazepam, alprazolam, and lorazepam in pain management identified no eligible studies, revealing a significant evidence gap despite decades of clinical use. This absence of comparative evidence prompted a broader narrative examination of the evidence base for benzodiazepines across pain conditions. Results: The available literature consistently fails to support benzodiazepine analgesia. Across 111 chronic pain conditions, analgesic benefit has been demonstrated for only two rare conditions: burning mouth syndrome (evidence primarily for topical clonazepam) and stiff person syndrome (primarily case series and clinical experience). In low back pain, the condition most associated with benzodiazepine prescribing, recent randomized trials show no benefit or even harm compared to placebo, and the only positive pooled evidence derived from trials of tetrazepam, a drug withdrawn from the European market in 2013. In rheumatoid arthritis, pooled data from six small trials show no benefit over placebo at any time point. The pharmacological basis for this clinical failure is now well characterized: conventional non-selective benzodiazepines produce dose-limiting sedation before achieving sufficient receptor occupancy at the α2/α3 GABA-A subtypes responsible for antihyperalgesic effects. Despite the lack of demonstrated efficacy, prescribing persists, likely driven by clinical inertia and patient expectations reflecting anxiolytic rather than analgesic properties. Guidelines from the WHO, NICE, the VA/DoD, the American College of Physicians, the American Academy of Family Physicians, and the Wilderness Medical Society uniformly recommend against benzodiazepine use for pain. This convergence of absent efficacy, well-documented harm, and unanimous guideline opposition supports the conclusion that benzodiazepines should not be prescribed as analgesic adjuvants. Conclusions: Although the focused search targeted head-to-head trials, a broader narrative synthesis and prior comprehensive reviews likewise demonstrate a paucity of high-quality evidence for benzodiazepine analgesia. Future research should focus on subtype-selective GABA-A modulators and on strategies to align clinical practice with the existing evidence, including structured deprescribing interventions.

10 November 2026 in Biochem
Verified
Journal Article
Open access
PDF file
CPCarolina Damas Pereira
Carolina Damas Pereira
GSGonçalo Silva
Gonçalo Silva
BSBeatriz Pereira Clemente de Sousa
Beatriz Pereira Clemente de Sousa
CPCarolina Portela
Carolina Portela
CTCarolina Vilela Teixeira
Carolina Vilela Teixeira
HRHugo Ribeiro
Hugo Ribeiro
Background: Methocarbamol is a centrally acting skeletal muscle relaxant widely used for musculoskeletal pain associated with muscle spasm, despite an incompletely understood mechanism of action and uncertainty regarding its efficacy compared with placebo or other pharmacological interventions. Objective: To evaluate the efficacy of methocarbamol in reducing pain intensity in adults (≥18 years) with acute or chronic pain, compared with placebo or other pharmacological interventions, and to assess its impact on quality of life and other pain-related outcomes. Methods: This systematic review was conducted according to the PRISMA 2020 statement and prospectively registered in PROSPERO (CRD420261440769). PubMed, Scopus, Web of Science, and Cochrane Library were searched from inception to 30 May 2026. Randomized and non-randomized controlled trials, cohort studies, case series, and narrative or systematic reviews reporting an extractable pain-related outcome were eligible. Risk of bias was assessed using RoB 2, ROBINS-I, or the Newcastle–Ottawa Scale, and level of evidence was graded per OCEBM 2011 criteria. Given substantial clinical and methodological heterogeneity, findings were synthesized narratively. Results: Twenty-eight studies (1959–2025; n = 30–9089), comprising 9 randomized controlled trials, 14 observational studies, 4 narrative/bibliographic reviews, and 1 case series, were included, spanning acute low back pain, postoperative/perioperative pain, trauma (including rib fractures), trigeminal neuralgia, cirrhosis-related muscle cramps, muscle strain, and opiate withdrawal. Results were inconsistent across indications: some trials showed benefit when methocarbamol was combined with NSAIDs or compared with opioids, while others—including the largest cohorts—found no advantage, partly attributable to confounding by indication. Opioid-sparing effects were observed in select postoperative and trauma populations. Methodological quality was generally moderate-to-high risk of bias. Conclusions: Evidence supporting methocarbamol’s analgesic efficacy is heterogeneous and inconclusive. Benefit appears most plausible in pain syndromes driven by muscle spasm, and it may have a role within multimodal, opioid-sparing strategies in selected postoperative and trauma settings. The available evidence is insufficient to support routine use across the clinical settings evaluated. Adequately powered, standardized randomized controlled trials are needed to clarify its true effect and identify patients most likely to benefit.